{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-303786","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2023-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.530766+00:00","generated_at":"2026-06-07T06:58:47.411442+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cytokinetics' aficamten Phase 3 success triggers $75M milestone for Royalty Pharma","bullets":["Cytokinetics announced positive Phase 3 SEQUOIA-HCM results for aficamten in symptomatic obstructive HCM.","Royalty Pharma holds a 4.5% global royalty on aficamten (3.5% on sales >$1B) as per Jan 2022 agreement.","Royalty Pharma provided $50M commercial launch capital; Cytokinetics can now draw $75M milestone.","Additional $100M milestone payable upon FDA acceptance of aficamten NDA.","Full results to be presented at upcoming medical conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-303786","json":"https://secwatch.observer/filing/0001193125-23-303786.json","markdown":"https://secwatch.observer/filing/0001193125-23-303786.md","text":"https://secwatch.observer/filing/0001193125-23-303786.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312523303786/0001193125-23-303786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312523303786/d615272d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:58:47.411442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}